Table 1 Patients’ characteristics and pre-AA history
Population (N = 306) | ||
|---|---|---|
Median [range] | ||
Age | 63 [46–82] | |
N | (%) | |
Initial Gleason score | ||
4 - 6 | 33 | (10.8%) |
7 | 92 | (30.0%) |
8 - 10 | 134 | (43.8%) |
missing | 47 | (15.4%) |
Sites of metastasis before CT | ||
Bone only | 144 | (47.1%) |
Visceral only | 57 | (18.6%) |
Multiple | 105 | (34.3%) |
Bone | 246 | (80.4%) |
Nodes | 133 | (43.5%) |
Lung | 22 | (7.2%) |
Liver | 17 | (5.6%) |
Brain | 1 | (0.3%) |
Other | 13 | (4.3%) |
Sites of metastasis before AA | ||
Bone only | 127 | (41.5%) |
Visceral only | 30 | (9.8%) |
Multiple | 149 | (48.7%) |
Bone | 275 | (89.9%) |
Nodes | 146 | (47.7%) |
Lung | 34 | (11.1%) |
Liver | 26 | (8.5%) |
Brain | 5 | (1.6%) |
Other | 18 | (5.9%) |
PSA before CT (ng/mL) | Median [range] | Missing |
45.4 [0–4967] | 37 (12.1%) | |
PSA before AA (ng/mL) | Median [range] | |
121.2 [0.15 - 8322] | 13 (4.2%) | |
Hormone treatment duration (months) | Median [range] | |
31.6 [0–201] | ||
CT treatment duration if one line (months) | Median [range | |
4.9 [0.3-20.7] | ||
CT treatment duration if more than 1 line (months) | Median [95% CI] | |
6.2 [0 – 50.2] | ||
Lines of CT before AA | Median [range] | |
1 [1-5] | ||
Number of lines of CT before AA | N | % |
1 | 170 | 55.6 |
2 | 103 | 33.7 |
3 | 20 | 6.5 |
4 | 10 | 3.3 |
5 | 3 | 1.0 |
Number of lines of CT after AA | N | % |
0 | 139 | 45.4 |
1 | 79 | 25.8 |
2 | 52 | 17 |
3 | 29 | 9.5 |
4 | 7 | 2.3 |
First line CT after AA (if applicable) | N | % |
Cabazitaxel | 51 | 30.6 |
Docetaxel rechallenge | 44 | 26.4 |
Distilbene | 17 | 10.2 |
Mitoxantrone | 14 | 8.5 |
Enzalutamide | 13 | 7.7 |
Other | 28 | 16.6 |